Study on AUNIP as a Novel Tumor Marker for Cervical Cancer
ConditionCervical Cancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age20-60
SponsorLin Yuan
About this trial
To detect the expression of AUNIP in cervical cancer serum, and to clarify its diagnostic and prognostic value.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Women aged 20-60
There is a definite pathological diagnosis of cervical cancer
Women aged 20-60
No tumors in the uterus or other parts of the body
Disqualifiers
There are other lesions in the uterus and uterine adnexa
Pregnant, lactating or menarche women
Women who are undergoing human papillomavirus (HPV) vaccination
Trial population
In this study, 150 patients with cervical cancer in the First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital) are selected as the study group. 150 healthy women are taken as control group during the same period.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Detection of serum AUNIP expression
Diagnostic testThe experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.
Treatment groups
300 Participants
are divided into 2 treatment groupsGroup A: study group1 intervention
Group B: Healthy control group1 intervention
Trial outcomes
Primary outcomes
1
AUNIP expression in serum
Serum AUNIP expression is detected by ELISA kit. The results will be recorded seperately.
Time frame
through study completion, an average of 3 yearLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Lin Yuan
Lead sponsor
Qianfoshan Hospital
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: